



(Made under the Regulation 4 (1))

	(Made under the Regula	ITION 4 (1))				
Applicati	on Number	TMDA use only				
Date of s	submission of the dossier	TMDA use only				
4.0	DANNIGTO A TIVE AND DOODUGT INFO	MATION				
	DMINISTRATIVE AND PRODUCT INFOI					
1.1	Type of the medicinal product application					
	New					
	Renewal*					
	* If variation has been made, information supporting the changes should be					
1.2	submitted (See TMDA variation guidelines for registered medicinal products)  Botanical name of the plant from which herbal substance is obtained					
1.2	Botamour name or the plant from which	nerbar substance is obtained				
1.3	Active herbal Substance and solvent used for extraction e.g cinchona root					
	bark 80% aqueous ethanol	•				
1.4	Strength of Active Herbal Substance pe	r unit dosage form				
		\				
1.5	Name and address (physical and postal	) of Applicant				
(Compai	ny) Name:					
	: Country:					
	ne: Telefax:					
E-mail:						
4.0						
1.6	Name and address (physical and postal	) of Applicant				
(Compa	) Nama:					
	ny) Name: Address:					
Postal a						
Region	uuless					
Country:						
Telepho						
Telefax:						
E-mail:						
1.7	Dosage form and route of administration	1				
1.7.1	Dosage form:					
1.7.2	Route(s) of administration					
1.8	Packing/pack size:					
1.9	Visual description (Add as many rows a	s necessary)				
	, , ,					

Effective Date: 21/10/2022





1.10	Proposed shelf life (in months):				
1.10.1	Proposed shelf life (after reconstitution or dilution):				
1.10.1	Proposed shelf life (after first opening container):				
1.10.2	1 0				
1.10.4	Proposed storage conditions:  Proposed storage conditions after first opening:				
1.10.4					
1.11.1	Other sister medicinal products registered or applied for registration				
1.11.1	Do you hold Marketing Authorization(s) of other medicinal product(s) containing				
	the same herbal substance(s) in the TMDA?				
	If yes state;				
	<ul> <li>Product name(s), strength(s), pharmaceutical dosage form(s):</li> </ul>				
	Partner States where product is authorized:     Marketing authorization number(a):				
	<ul><li>Marketing authorization number(s):</li><li>Indication(s):</li></ul>				
1.11.2	Have you applied for marketing authorization medicinal product(s)				
	containing the same active substance(s) in the TMDA?				
	If yes state;				
	<ul><li>Product name(s), strength(s), pharmaceutical dosage form(s):</li></ul>				
	Indication(s):				
1.12	Pharmacotherapeutic group and ATC Code				
1.12.1	Pharmacotherapeutic group:				
1.12.3	If no ATC code has been assigned, please indicate if an application for ATC				
	code has been made:				
4.40					
1.13	Distribution category: Controlled Drug POM Pharmacy Only				
	OTC General sale				
	(Applicants are invited to indicate which categories they are requesting,				
	however, the NMRAs reserve the right to change and/or apply only those categories provided for in their national legislation)				
1.14	Country of origin:				
1.12	Pharmacotherapeutic group and ATC Code				
1.12.1	Pharmacotherapeutic group:				
1.12.3	If no ATC code has been assigned, please indicate if an application for ATC				
	code has been made:				
1.13	Distribution category: Controlled Drug POM Pharmacy Only				
	OTC General sale				
	(Applicants are invited to indicate which categories they are requesting,				
	however, the NMRAs reserve the right to change and/or apply only those				
4 4 4	categories provided for in their national legislation)				
1.14	Country of origin:				
1.15	Product Marketing Authorization in the country of origin (Attach Certificate of				
	Pharmaceutical Product or free sale certificate from National Medicines				
	Regulatory Authority). If not registered, state reasons				





□ Date of authorization (dd-mm-			☐ Withdrawn (by applicant after authorization)		
уууу):			Country:		
Proprietary name:			Date of withdrawal (dd-mm-yyyy):		
Authoriza	ition number:		Proprietary name:		
			Reason for withdrawal:		
□ Refuse	□ Refused				
Countr	y:		Suspended/revoked (by competent	authority)	
Date of	f refusal (dd-mm-yyyy):		Country:		
Reaso	n for Refusal:		Date of suspension/revocation (dd-	mm-yyyy):	
			Reason for suspension/revocation:		
			Proprietary name:		
1.16	Name(s) and complete physical address(es) of the manufacturer(s)				
1.16.1	Name(s) and physical	addr	ress (es) of the manufacturing site	of the	
			PP), including the final product rele		
			turer. Alternative sites should be a		
	declared here.				
	state the role of each sit	е			
	(Add as many rows as n	eces	ssary)		
Name:					
Compan	•				
Address					
Country:					
Telepho	ne:				
Telefax:					
E-Mail:	Nome (a) and planting				
1.16.2			ress(es) of the manufacturer(s) of the diameter (s) (ARI)	ne	
	active pharmaceutical				
	(Add as many rows as n		ved in the manufacturing process of the	no horbal	
	substance should be list	ed.	ved in the manufacturing process of the	ie Herbai	
Name:					
Compan	ıv name:				
Address	•				
Country:					
Telephone:					
Telefax:					
E-Mail:					
1.17	Name and address (physical and postal) of the local				





NI								
Name:								
Company name:								
Address:								
Country	ountry:							
Telepho								
Telefax:								
E-Mail:								
1.18	State the reference/monograph standard such as WHO monograph of							
	selected medic	cinal plants, British Pharn	nacopeia, United States					
	Pharmacopeia	, Ph. Eur, Japanese Pha	rmacopeia, In-house mo	nograph				
		nerbal substance	•					
	Qualitative and	and Quantitative composition of the active substance(s) and						
1.19	excipient(s)	•		. ,				
	A note should	be given as to which qua	ntity the composition refe	ers (e.g. 1				
	capsule).	3	,	` 3				
Name	of	Quantity /	Unit of measure	Reference/				
active		dosage unit		monograph				
ingredi	ent(s)*							
1.								
2.								
3.								
4.								
e.t.c								
	Excipient(s)							
1.	LXCIPICITI(3)	1	1					
2.								
1 1								
3.								
4.								
e.t.c								
_	Name and add	ress (physical and posta	I) of the Contract Resear	ch				
1.20	Organisation (s) where the clinical studies of the product were conducted.							
	- 3. 3 (a) miles and emilear stadios of the product word contiducted.							
Name:								
Compar	ny name:							
Address:								
	Country:							
-	Telephone:							
Telefax:								
E-Mail:								





#### 2.0 DECLARATION BY AN APPLICANT

I, the undersigned certify that all the information in this form and accompanying documentation is correct, complete and true to the best of my knowledge.

I further confirm that the information referred to in my application dossier is available for verification during GMP inspection.

I also agree that I shall carry out pharmacovigilance to monitor the safety of the product in the market and provide safety update reports to the TMDA.

I further agree that I am obliged to follow the requirements of the TMDA Legislations and Regulations which are applicable to medicinal products.

I also consent to the processing of information provided by the TMDA.

It is hereby confirmed that fees will be paid/have been paid according to the TMDA Fees and Charges Regulations\*

Name:	
Signature:  Date:  Official stamp:	

\* Note: If fees have been paid, attach proof of payment